



WHAT IS CLAIMED IS:

1. A compound having the structure of Formula I:



5 wherein  is a monocyclic or bicyclic aromatic moiety in which at least one of the ring atoms is N and selected from the group consisting of:



L is selected from the group consisting of a bond and CH₂;

k is 1, 2, or 3;

10 R₁ and R₂ are each independently selected from the group consisting of

a) alkyl, optionally substituted with a substituent selected from the group consisting of hydrogen, lower alkyl, optionally substituted carbocyclic or heterocyclic ring, halogen, perhaloalkyl, hydroxy, alkoxy, nitro, and amino;

15 b) a six-membered carbocyclic aromatic moiety, or a monocyclic or bicyclic aromatic moiety in which at least one ring atom is N, wherein any such aromatic moiety is optionally substituted with one or more substituents selected from the group consisting of

20 A) optionally substituted C₁-C₈ straight-chain, branched, or cyclic saturated or unsaturated alkyl;

B) an alkoxy of formula -(X₁)_n-O-X₂, where

X₁ is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_2 is selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; and $n1$ is 0 or 1;

5 C) halogen or perhaloalkyl;

D) cyano;

E) nitro;

F) an amino of formula $-(X_3)_{n3}-NX_4X_5$, where

X_3 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

10

X_4 and X_5 are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; or X_4 and X_5 , taken together with the nitrogen to which they are attached, form a five-membered or six-membered heteroaromatic or heteroaliphatic ring; and

15

$n3$ is 0 or 1;

c) perhaloalkyl;

d) halogen; and

20 e) acyl and sulfonyl;

Each R_3 is independently selected from the group consisting of

a) hydrogen;

25 b) alkyl, optionally substituted with a substituent selected from the group consisting of hydrogen, lower alkyl, optionally substituted carbocyclic or heterocyclic ring, halogen, perhaloalkyl, hydroxy, alkoxy, nitro, and amino;

c) a five-membered or six-membered heteroaryl ring or a six-membered aryl ring, optionally substituted with one or more substituents selected from the group consisting of

30 A) optionally substituted C_1-C_8 straight-chain, branched, or cyclic saturated or unsaturated alkyl;

B) an alkoxy of formula $-(X_1)_{n1}-O-X_2$, where

X₁ is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

5 X₂ is selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; and n1 is 0 or 1;

C) halogen or perhaloalkyl;

D) cyano;

E) nitro;

10 F) an amino of formula -(X₃)_{n3}-NX₄X₅, where

X₃ is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

15 X₄ and X₅ are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; or X₄ and X₅, taken together with the nitrogen to which they are attached, form a five-membered or six-membered heteroaromatic or heteroaliphatic ring; and

20 n3 is 0 or 1;

d) perhaloalkyl;

e) halogen; and

f) acyl and sulfonyl; and

R₄ is selected from the group consisting of


25 a) hydrogen;

b) alkyl, optionally substituted with a substituent selected from the group consisting of hydrogen, lower alkyl, optionally substituted carbocyclic or heterocyclic ring; and

30 c) a five-membered or six-membered heteroaryl ring or a six-membered aryl ring, optionally substituted with one or more substituents selected from the group consisting of optionally substituted C₁-C₈ straight-chain, branched, or cyclic saturated or unsaturated alkyl;

or a pharmaceutically acceptable N-oxide, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester, pharmaceutically acceptable amide, or pharmaceutically acceptable solvate thereof.

5 2. The compound of Claim 1 selected from the group consisting of:



wherein Ar₂ is a monocyclic or bicyclic aromatic moiety in which at least one of the ring atoms is N;
 10 one of Q₁ - Q₅ is nitrogen and the rest are carbon, wherein said carbon is optionally substituted with hydrogen, R₃, or -C(O)OR₄; and
 R₅ is selected from the group consisting of

- a) hydrogen;
- 15 b) alkyl, optionally substituted with a substituent selected from the group consisting of hydrogen, lower alkyl, optionally substituted carbocyclic or heterocyclic ring, halogen, perhaloalkyl, hydroxy, alkoxy, nitro, and amino;
- c) a five-membered or six-membered heteroaryl ring or a six-membered aryl ring, optionally substituted with one or more substituents selected from the group consisting of
- 20 A) optionally substituted C₁-C₈ straight-chain, branched, or cyclic saturated or unsaturated alkyl;

5 B) an alkoxy of formula $-(X_1)_{n1}-O-X_2$, where

X_1 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

10 X_2 is selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; and
 $n1$ is 0 or 1;

15 C) halogen or perhaloalkyl;

D) cyano;

E) nitro;

20 F) an amino of formula $-(X_3)_{n3}-NX_4X_5$, where

X_3 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;


25 X_4 and X_5 are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; or X_4 and X_5 , taken together with the nitrogen to which they are attached, form a five-membered or six-membered heteroaromatic or heteroaliphatic ring; and
 $n3$ is 0 or 1;

d) perhaloalkyl;


e) halogen; and

f) acyl and sulfonyl.


3. The compound of Claim 2 having the structure:




wherein Ar_2 is selected from the group consisting of:




4. The compound of Claim 3, wherein R_1 is alkyl, optionally substituted with one or more optionally substituted carbocyclic or heterocyclic rings.
5. The compound of Claim 4, wherein said alkyl is a lower alkyl.
6. The compound of Claim 5, wherein said lower alkyl is selected from the 5 group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, and sec-butyl.
7. The compound of Claim 4, wherein said carbocyclic ring is phenyl.
8. The compound of Claim 7, wherein said phenyl is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, halogen, perhaloalkyl, hydroxy, alkoxy, nitro, and amino.
- 10 9. The compound of Claim 8, wherein said substituent is perhaloalkyl.
10. The compound of Claim 9, wherein said perhaloalkyl is trifluoromethyl.
11. The compound of Claim 4, wherein the carbocyclic ring is 2,4-bis(trifluoromethyl)phenyl.
12. The compound of Claim 3, wherein R_5 is optionally substituted alkyl.
- 15 13. The compound of Claim 12, wherein said alkyl is a lower alkyl.
14. The compound of Claim 13, wherein said lower alkyl is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, and sec-butyl.
15. The compound of Claim 14, wherein R_5 is ethyl.
16. The compound of Claim 3, wherein R_3 is hydrogen or optionally 20 substituted alkyl.
17. The compound of Claim 16, wherein said alkyl is a lower alkyl.
18. The compound of Claim 17, wherein said lower alkyl is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, and sec-butyl.
19. The compound of Claim 3, wherein R_3 is methyl.
- 25 20. The compound of Claim 3, wherein R_3 is hydrogen.
21. The compound of Claim 3, wherein R_4 is hydrogen or optionally substituted alkyl.
22. The compound of Claim 21, wherein said alkyl is a lower alkyl.
23. The compound of Claim 22, wherein said lower alkyl is selected from the 30 group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, and sec-butyl.
24. The compound of Claim 21, wherein R_4 is hydrogen.
25. The compound of Claim 3, wherein Ar_2 is



26. The compound of Claim 3, wherein Ar₂ is




27. The compound of Claim 3, wherein Ar₂ is





5


28. The compound of Claim 3, wherein Ar₂ is




29. The compound of Claim 3 selected from the group consisting of







30. The compound of Claim 3 selected from the group consisting of




, or a pharmaceutically

acceptable N-oxide, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester,

5 pharmaceutically acceptable amide, or pharmaceutically acceptable solvate thereof.

31. The compound of Claim 3 selected from the group consisting of




, or a pharmaceutically

acceptable N-oxide, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester,

10 pharmaceutically acceptable amide, or pharmaceutically acceptable solvate thereof..

32. The compound of Claim 3 selected from the group consisting of




, or a pharmaceutically


acceptable N-oxide, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester,

15 pharmaceutically acceptable amide, or pharmaceutically acceptable solvate thereof.

33. The compound of Claim 2 having the structure:




wherein Ar₂ is selected from the group consisting of:




20 34. The compound of Claim 33, wherein R₁ is alkyl, optionally substituted with one or more optionally substituted carbocyclic or heterocyclic rings.


- 35. The compound of Claim 34, wherein said alkyl is a lower alkyl.
- 36. The compound of Claim 35, wherein said lower alkyl is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, and sec-butyl.
- 37. The compound of Claim 34, wherein said carbocyclic ring is phenyl.
- 5 38. The compound of Claim 37, wherein said phenyl is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, halogen, perhaloalkyl, hydroxy, alkoxy, nitro, and amino.
- 39. The compound of Claim 38, wherein said substituent is perhaloalkyl.
- 40. The compound of Claim 39, wherein said perhaloalkyl is trifluoromethyl.
- 10 41. The compound of Claim 34, wherein carbocyclic ring is 2,4-bis(trifluoromethyl)phenyl.
- 42. The compound of Claim 33, wherein R₅ is optionally substituted alkyl.
- 43. The compound of Claim 42, wherein said alkyl is a lower alkyl.
- 44. The compound of Claim 43, wherein said lower alkyl is selected from the
- 15 group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, and sec-butyl.
- 45. The compound of Claim 33, wherein R₅ is ethyl.
- 46. The compound of Claim 33, wherein R₃ is hydrogen, halogen or optionally substituted alkyl.
- 47. The compound of Claim 46, wherein said alkyl is a lower alkyl.
- 20 48. The compound of Claim 47, wherein said lower alkyl is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, and sec-butyl.
- 49. The compound of Claim 33, wherein R₃ is methyl.
- 50. The compound of Claim 33, wherein R₃ is hydrogen.
- 51. The compound of Claim 33, wherein R₄ is hydrogen or optionally
- 25 substituted alkyl.
- 52. The compound of Claim 51, wherein said alkyl is a lower alkyl.
- 53. The compound of Claim 52, wherein said lower alkyl is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, and sec-butyl.
- 54. The compound of Claim 51, wherein R₄ is hydrogen.
- 30 55. The compound of Claim 33, wherein Ar₂ is




- 56. The compound of Claim 33, wherein Ar₂ is




57. The compound of Claim 33, wherein Ar₂ is




58. The compound of Claim 33, wherein Ar₂ is



59. The compound of Claim 33 selected from the group consisting of






or a pharmaceutically acceptable N-oxide, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester, pharmaceutically acceptable amide, or pharmaceutically acceptable solvate thereof.


5 acceptable ester, pharmaceutically acceptable amide, or pharmaceutically acceptable solvate thereof.

60. The compound of Claim 33 selected from the group consisting of




acceptable N-oxide, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester, pharmaceutically acceptable amide, or pharmaceutically acceptable solvate thereof.

61. The compound of Claim 33 selected from the group consisting of




pharmaceutically acceptable N-oxide, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester, pharmaceutically acceptable amide, or pharmaceutically acceptable solvate thereof.

62. The compound of Claim 33 selected from the group consisting of




, or a pharmaceutically acceptable N-oxide, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester, pharmaceutically acceptable amide, or pharmaceutically acceptable solvate thereof.

5 63. The compound of Claim 2 having the structure:



wherein Ar₂ is selected from the group consisting of:



64. The compound of Claim 63, wherein R₁ is alkyl, optionally substituted with one or more optionally substituted carbocyclic or heterocyclic rings.

10 65. The compound of Claim 64, wherein said alkyl is a lower alkyl.

66. The compound of Claim 65, wherein said lower alkyl is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, and sec-butyl.

15 67. The compound of Claim 64, wherein said carbocyclic ring is phenyl.

68. The compound of Claim 67, wherein said phenyl is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, halogen, perhaloalkyl, hydroxy, alkoxy, nitro, and amino.

69. The compound of Claim 68, wherein said substituent is perhaloalkyl.

70. The compound of Claim 69, wherein said perhaloalkyl is trifluoromethyl.

20 71. The compound of Claim 64, wherein the carbocyclic ring is 2,4-bis(trifluoromethyl)phenyl.

72. The compound of Claim 63, wherein R₅ is optionally substituted alkyl.

73. The compound of Claim 72, wherein said alkyl is a lower alkyl.

74. The compound of Claim 73, wherein said lower alkyl is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, and sec-butyl.

25 75. The compound of Claim 63, wherein R₅ is ethyl.

76. The compound of Claim 63, wherein R₃ is hydrogen, halogen, or optionally substituted alkyl.

77. The compound of Claim 76, wherein said alkyl is a lower alkyl.

78. The compound of Claim 77, wherein said lower alkyl is selected from the 5 group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, and sec-butyl.

79. The compound of Claim 63, wherein R₃ is methyl.

80. The compound of Claim 63, wherein R₃ is hydrogen.

81. The compound of Claim 63, wherein R₃ is halogen, selected from the group consisting of fluoro, chloro, and bromo.

10 82. The compound of Claim 63, wherein R₃ is chloro.

83. The compound of Claim 63, wherein R₄ is hydrogen or optionally substituted alkyl.

84. The compound of Claim 83, wherein said alkyl is a lower alkyl.

85. The compound of Claim 84, wherein said lower alkyl is selected from the 15 group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, and sec-butyl.

86. The compound of Claim 83, wherein R₄ is hydrogen.

87. The compound of Claim 63, wherein Ar₂ is


20

88. The compound of Claim 63, wherein Ar₂ is


89. The compound of Claim 63, wherein Ar₂ is

90. The compound of Claim 63, wherein Ar₂ is

25 91. The compound of Claim 63 selected from the group consisting of




92. The compound of Claim 63 selected from the group consisting of




pharmaceutically acceptable prodrug, pharmaceutically active metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester, pharmaceutically acceptable amide, or pharmaceutically acceptable solvate thereof.

10 93. The compound of Claim 63 selected from the group consisting of



pharmaceutically acceptable prodrug, pharmaceutically active metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester, pharmaceutically acceptable amide, or pharmaceutically acceptable solvate thereof.

10 94. The compound of Claim 63 selected from the group consisting of



pharmaceutically acceptable prodrug, pharmaceutically active metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester, pharmaceutically acceptable amide, or pharmaceutically acceptable solvate thereof.

10 95. A compound selected from the group consisting of KP001 through KP190, KP001-1ET through KP190-1ET, KP001-2ET through KP190-2ET, KP006-9CL through KP008-9CL, KP010-9CL, KP016-9CL through KP018-9CL, KP020-9CL, KP026-9CL through KP028-9CL, KP030-9CL, KP036-9CL through KP038-9CL, KP040-9CL, KP046-9CL through KP048-9CL, KP050-9CL, KP056-9CL through KP058-9CL,
15 KP060-9CL, KP066-9CL through KP068-9CL, KP070-9CL, KP076-9CL through KP078-9CL, KP080-9CL, KP086-9CL through KP088-9CL, KP090-9CL, KP096-9CL

through KP098-9CL, KP100-9CL, KP106-9CL through KP108-9CL, KP110-9CL, KP116-9CL through KP118-9CL, KP120-9CL, KP126-9CL through KP128-9CL, KP130-9CL, KP136-9CL through KP138-9CL, KP140-9CL, KP146-9CL through KP148-9CL, KP150-9CL, KP156-9CL through KP158-9CL, KP160-9CL, KP166-9CL
5 through KP168-9CL, KP170-9CL, KP176-9CL through KP178-9CL, KP180-9CL, KP186-9CL through KP188-9CL, KP190-9CL, KP006-1ET-9CL through KP008-1ET-9CL, KP010-1ET-9CL, KP016-1ET-9CL through KP018-1ET-9CL, KP020-1ET-9CL, KP026-1ET-9CL through KP028-1ET-9CL, KP030-1ET-9CL, KP036-1ET-9CL through KP038-1ET-9CL, KP040-1ET-9CL, KP046-1ET-9CL through KP048-1ET-9CL, KP050-
10 1ET-9CL, KP056-1ET-9CL through KP058-1ET-9CL, KP060-1ET-9CL, KP066-1ET-9CL through KP068-1ET-9CL, KP070-1ET-9CL, KP076-1ET-9CL through KP078-1ET-9CL, KP080-1ET-9CL, KP086-1ET-9CL through KP088-1ET-9CL, KP090-1ET-9CL, KP096-1ET-9CL through KP098-1ET-9CL, KP100-1ET-9CL, KP106-1ET-9CL through KP108-1ET-9CL, KP110-1ET-9CL, KP116-1ET-9CL through KP118-1ET-9CL, KP120-
15 1ET-9CL, KP126-1ET-9CL through KP128-1ET-9CL, KP130-1ET-9CL, KP136-1ET-9CL through KP138-1ET-9CL, KP140-1ET-9CL, KP146-1ET-9CL through KP148-1ET-9CL, KP150-1ET-9CL, KP156-1ET-9CL through KP158-1ET-9CL, KP160-1ET-9CL, KP166-1ET-9CL through KP168-1ET-9CL, KP170-1ET-9CL, KP176-1ET-9CL through KP178-1ET-9CL, KP180-1ET-9CL, KP186-1ET-9CL through KP188-1ET-9CL, KP190-
20 1ET-9CL, KP006-2ET-9CL through KP008-2ET-9CL, KP010-2ET-9CL, KP016-2ET-9CL through KP018-2ET-9CL, KP020-2ET-9CL, KP026-2ET-9CL through KP028-2ET-9CL, KP030-2ET-9CL, KP036-2ET-9CL through KP038-2ET-9CL, KP040-2ET-9CL, KP046-2ET-9CL through KP048-2ET-9CL, KP050-2ET-9CL, KP056-2ET-9CL through KP058-2ET-9CL, KP060-2ET-9CL, KP066-2ET-9CL through KP068-2ET-9CL, KP070-
25 2ET-9CL, KP076-2ET-9CL through KP078-2ET-9CL, KP080-2ET-9CL, KP086-2ET-9CL through KP088-2ET-9CL, KP090-2ET-9CL, KP096-2ET-9CL through KP098-2ET-9CL, KP100-2ET-9CL, KP106-2ET-9CL through KP108-2ET-9CL, KP110-2ET-9CL, KP116-2ET-9CL through KP118-2ET-9CL, KP120-2ET-9CL, KP126-2ET-9CL through KP128-2ET-9CL, KP130-2ET-9CL, KP136-2ET-9CL through KP138-2ET-9CL, KP140-
30 2ET-9CL, KP146-2ET-9CL through KP148-2ET-9CL, KP150-2ET-9CL, KP156-2ET-9CL through KP158-2ET-9CL, KP160-2ET-9CL, KP166-2ET-9CL through KP168-2ET-9CL, KP170-2ET-9CL, KP176-2ET-9CL through KP178-2ET-9CL, KP180-2ET-9CL, KP186-2ET-9CL through KP188-2ET-9CL, KP190-2ET-9CL, KP002-10CL through

KP004-10CL, KP009-10CL, KP012-10CL through KP014-10CL, KP019-10CL, KP022-10CL through KP024-10CL, KP029-10CL, KP032-10CL through KP034-10CL, KP039-10CL, KP042-10CL through KP044-10CL, KP049-10CL, KP052-10CL through KP054-10CL, KP059-10CL, KP062-10CL through KP064-10CL, KP069-10CL, KP072-10CL

5 through KP074-10CL, KP079-10CL, KP082-10CL through KP084-10CL, KP089-10CL, KP092-10CL through KP094-10CL, KP099-10CL, KP102-10CL through KP104-10CL, KP109-10CL, KP112-10CL through KP114-10CL, KP119-10CL, KP122-10CL through KP124-10CL, KP129-10CL, KP132-10CL through KP134-10CL, KP139-10CL, KP142-10CL through KP144-10CL, KP149-10CL, KP152-10CL through KP154-10CL, KP159-

10 10CL, KP166-10CL through KP164-10CL, KP169-10CL, KP172-10CL through KP174-10CL, KP179-10CL, KP182-10CL through KP184-10CL, KP189-10CL, KP002-1ET-10CL through KP004-1ET-10CL, KP009-1ET-10CL, KP012-1ET-10CL through KP014-1ET-10CL, KP019-1ET-10CL, KP022-1ET-10CL through KP024-1ET-10CL, KP029-1ET-10CL, KP032-1ET-10CL through KP034-1ET-10CL, KP039-1ET-10CL, KP042-

15 1ET-10CL through KP044-1ET-10CL, KP049-1ET-10CL, KP052-1ET-10CL through KP054-1ET-10CL, KP059-1ET-10CL, KP062-1ET-10CL through KP064-1ET-10CL, KP069-1ET-10CL, KP072-1ET-10CL through KP074-1ET-10CL, KP079-1ET-10CL, KP082-1ET-10CL through KP084-1ET-10CL, KP089-1ET-10CL, KP092-1ET-10CL through KP094-1ET-10CL, KP099-1ET-10CL, KP102-1ET-10CL through KP104-1ET-

20 10CL, KP109-1ET-10CL, KP112-1ET-10CL through KP114-1ET-10CL, KP119-1ET-10CL, KP122-1ET-10CL through KP124-1ET-10CL, KP129-1ET-10CL, KP132-1ET-10CL through KP134-1ET-10CL, KP139-1ET-10CL, KP142-1ET-10CL through KP144-1ET-10CL, KP149-1ET-10CL, KP152-1ET-10CL through KP154-1ET-10CL, KP159-1ET-10CL, KP162-1ET-10CL through KP164-1ET-10CL, KP169-1ET-10CL, KP172-

25 1ET-10CL through KP174-1ET-10CL, KP179-1ET-10CL, KP182-1ET-10CL through KP184-1ET-10CL, KP189-1ET-10CL, KP002-2ET-10CL through KP004-2ET-10CL, KP009-2ET-10CL, KP012-2ET-10CL through KP014-2ET-10CL, KP019-2ET-10CL, KP022-2ET-10CL through KP024-2ET-10CL, KP029-2ET-10CL, KP032-2ET-10CL through KP034-2ET-10CL, KP039-2ET-10CL, KP042-2ET-10CL through KP044-2ET-

30 10CL, KP049-2ET-10CL, KP052-2ET-10CL through KP054-2ET-10CL, KP059-2ET-10CL, KP062-2ET-10CL through KP064-2ET-10CL, KP069-2ET-10CL, KP072-2ET-10CL through KP074-2ET-10CL, KP079-2ET-10CL, KP082-2ET-10CL through KP084-2ET-10CL, KP089-2ET-10CL, KP092-2ET-10CL through KP094-2ET-10CL, KP099-

2ET-10CL, KP102-2ET-10CL through KP104-2ET-10CL, KP109-2ET-10CL, KP112-2ET-10CL through KP114-2ET-10CL, KP119-2ET-10CL, KP122-2ET-10CL through KP124-2ET-10CL, KP129-2ET-10CL, KP132-2ET-10CL through KP134-2ET-10CL, KP139-2ET-10CL, KP142-2ET-10CL through KP144-2ET-10CL, KP149-2ET-10CL,
5 KP152-2ET-10CL through KP154-2ET-10CL, KP159-2ET-10CL, KP162-2ET-10CL through KP164-2ET-10CL, KP169-2ET-10CL, KP172-2ET-10CL through KP174-2ET-10CL, KP179-2ET-10CL, KP182-2ET-10CL through KP184-2ET-10CL, KP189-2ET-10CL, KP001-11CL, KP003-11CL through KP005-11CL, KP007-11CL, KP008-11CL, KP011-11CL, KP013-11CL through KP015-11CL, KP017-11CL, KP018-11CL, KP021-11CL, KP023-11CL through KP025-11CL, KP027-11CL, KP028-11CL, KP031-11CL, KP033-11CL through KP035-11CL, KP037-11CL, KP038-11CL, KP041-11CL, KP043-11CL through KP045-11CL, KP047-11CL, KP048-11CL, KP051-11CL, KP053-11CL through KP055-11CL, KP057-11CL, KP058-11CL, KP061-11CL, KP063-11CL through KP065-11CL, KP067-11CL, KP068-11CL, KP071-11CL, KP073-11CL through KP075-11CL, KP077-11CL, KP078-11CL, KP081-11CL, KP083-11CL through KP085-11CL, KP087-11CL, KP088-11CL, KP091-11CL, KP093-11CL through KP095-11CL, KP097-11CL, KP098-11CL, KP101-11CL, KP103-11CL through KP105-11CL, KP107-11CL, KP108-11CL, KP111-11CL, KP113-11CL through KP115-11CL, KP117-11CL, KP118-11CL, KP121-11CL, KP123-11CL through KP125-11CL, KP127-11CL, KP128-11CL,
20 KP131-11CL, KP133-11CL through KP135-11CL, KP137-11CL, KP138-11CL, KP141-11CL, KP143-11CL through KP145-11CL, KP147-11CL, KP148-11CL, KP151-11CL, KP153-11CL through KP155-11CL, KP157-11CL, KP158-11CL, KP161-11CL, KP163-11CL through KP165-11CL, KP167-11CL, KP168-11CL, KP171-11CL, KP173-11CL through KP175-11CL, KP177-11CL, KP178-11CL, KP181-11CL, KP183-11CL through
25 KP185-11CL, KP187-11CL, KP188-11CL, KP001-1ET-11CL, KP003-1ET-11CL through KP005-1ET-11CL, KP007-1ET-11CL, KP008-1ET-11CL, KP011-1ET-11CL, KP013-1ET-11CL through KP015-1ET-11CL, KP017-1ET-11CL, KP018-1ET-11CL, KP021-1ET-11CL, KP023-1ET-11CL through KP025-1ET-11CL, KP027-1ET-11CL, KP028-1ET-11CL, KP031-1ET-11CL, KP033-1ET-11CL through KP035-1ET-11CL,
30 KP037-1ET-11CL, KP038-1ET-11CL, KP041-1ET-11CL, KP043-1ET-11CL through KP045-1ET-11CL, KP047-1ET-11CL, KP048-1ET-11CL, KP051-1ET-11CL, KP053-1ET-11CL through KP055-1ET-11CL, KP057-1ET-11CL, KP058-1ET-11CL, KP061-1ET-11CL, KP063-1ET-11CL through KP065-1ET-11CL, KP067-1ET-11CL, KP068-

1ET-11CL, KP071-1ET-11CL, KP073-1ET-11CL through KP075-1ET-11CL, KP077-
1ET-11CL, KP078-1ET-11CL, KP081-1ET-11CL, KP083-1ET-11CL through KP085-
1ET-11CL, KP087-1ET-11CL, KP088-1ET-11CL, KP091-1ET-11CL, KP093-1ET-11CL
through KP095-1ET-11CL, KP097-1ET-11CL, KP098-1ET-11CL, KP101-1ET-11CL,
5 KP103-1ET-11CL through KP105-1ET-11CL, KP107-1ET-11CL, KP108-1ET-11CL,
KP111-1ET-11CL, KP113-1ET-11CL through KP115-1ET-11CL, KP117-1ET-11CL,
KP118-1ET-11CL, KP121-1ET-11CL, KP123-1ET-11CL through KP125-1ET-11CL,
KP127-1ET-11CL, KP128-1ET-11CL, KP131-1ET-11CL, KP133-1ET-11CL through
KP135-1ET-11CL, KP137-1ET-11CL, KP138-1ET-11CL, KP141-1ET-11CL, KP143-
10 1ET-11CL through KP145-1ET-11CL, KP147-1ET-11CL, KP148-1ET-11CL, KP151-
1ET-11CL, KP153-1ET-11CL through KP155-1ET-11CL, KP157-1ET-11CL, KP158-
1ET-11CL, KP161-1ET-11CL, KP163-1ET-11CL through KP165-1ET-11CL, KP167-
1ET-11CL, KP168-1ET-11CL, KP171-1ET-11CL, KP173-1ET-11CL through KP175-
1ET-11CL, KP177-1ET-11CL, KP178-1ET-11CL, KP181-1ET-11CL, KP183-1ET-11CL
15 through KP185-1ET-11CL, KP187-1ET-11CL, KP188-1ET-11CL, KP001-2ET-11CL,
KP003-2ET-11CL through KP005-2ET-11CL, KP007-2ET-11CL, KP008-2ET-11CL,
KP011-2ET-11CL, KP013-2ET-11CL through KP015-2ET-11CL, KP017-2ET-11CL,
KP018-2ET-11CL, KP021-2ET-11CL, KP023-2ET-11CL through KP025-2ET-11CL,
KP027-2ET-11CL, KP028-2ET-11CL, KP031-2ET-11CL, KP033-2ET-11CL through
20 KP035-2ET-11CL, KP037-2ET-11CL, KP038-2ET-11CL, KP041-2ET-11CL, KP043-
2ET-11CL through KP045-2ET-11CL, KP047-2ET-11CL, KP048-2ET-11CL, KP051-
2ET-11CL, KP053-2ET-11CL through KP055-2ET-11CL, KP057-2ET-11CL, KP058-
2ET-11CL, KP061-2ET-11CL, KP063-2ET-11CL through KP065-2ET-11CL, KP067-
2ET-11CL, KP068-2ET-11CL, KP071-2ET-11CL, KP073-2ET-11CL through KP075-
25 2ET-11CL, KP077-2ET-11CL, KP078-2ET-11CL, KP081-2ET-11CL, KP083-2ET-11CL
through KP085-2ET-11CL, KP087-2ET-11CL, KP088-2ET-11CL, KP091-2ET-11CL,
KP093-2ET-11CL through KP095-2ET-11CL, KP097-2ET-11CL, KP098-2ET-11CL,
KP101-2ET-11CL, KP103-2ET-11CL through KP105-2ET-11CL, KP107-2ET-11CL,
KP108-2ET-11CL, KP111-2ET-11CL, KP113-2ET-11CL through KP115-2ET-11CL,
30 KP117-2ET-11CL, KP118-2ET-11CL, KP121-2ET-11CL, KP123-2ET-11CL through
KP125-2ET-11CL, KP127-2ET-11CL, KP128-2ET-11CL, KP131-2ET-11CL, KP133-
2ET-11CL through KP135-2ET-11CL, KP137-2ET-11CL, KP138-2ET-11CL, KP141-
2ET-11CL, KP143-2ET-11CL through KP145-2ET-11CL, KP147-2ET-11CL, KP148-

2ET-11CL, KP151-2ET-11CL, KP153-2ET-11CL through KP155-2ET-11CL, KP157-
2ET-11CL, KP158-2ET-11CL, KP161-2ET-11CL, KP163-2ET-11CL through KP165-
2ET-11CL, KP167-2ET-11CL, KP168-2ET-11CL, KP171-2ET-11CL, KP173-2ET-11CL
through KP175-2ET-11CL, KP177-2ET-11CL, KP178-2ET-11CL, KP181-2ET-11CL,
5 KP183-2ET-11CL through KP185-2ET-11CL, KP187-2ET-11CL, KP188-2ET-11CL,
KP001-12CL, KP002-12CL, KP004-12CL through KP007-12CL, KP008-12CL through
KP012-12CL, KP014-12CL through KP017-12CL, KP018-12CL through KP022-12CL,
KP024-12CL through KP027-12CL, KP028-12CL through KP032-12CL, KP034-12CL
through KP037-12CL, KP038-12CL through KP042-12CL, KP044-12CL through
10 KP047-12CL, KP048-12CL through KP052-12CL, KP054-12CL through KP057-12CL,
KP058-12CL through KP062-12CL, KP064-12CL through KP067-12CL, KP068-12CL
through KP072-12CL, KP074-12CL through KP077-12CL, KP078-12CL through
KP082-12CL, KP084-12CL through KP087-12CL, KP088-12CL through KP092-12CL,
KP094-12CL through KP097-12CL, KP098-12CL through KP102-12CL, KP104-12CL
15 through KP107-12CL, KP108-12CL through KP112-12CL, KP114-12CL through
KP117-12CL, KP118-12CL through KP122-12CL, KP124-12CL through KP127-12CL,
KP128-12CL through KP132-12CL, KP134-12CL through KP137-12CL, KP138-12CL
through KP142-12CL, KP144-12CL through KP147-12CL, KP148-12CL through
KP152-12CL, KP154-12CL through KP157-12CL, KP158-12CL through KP162-12CL,
20 KP164-12CL through KP167-12CL, KP168-12CL through KP172-12CL, KP174-12CL
through KP177-12CL, KP178-12CL through KP182-12CL, KP184-12CL through
KP187-12CL, KP188-12CL through KP190-12CL, KP001-1ET-12CL, KP002-1ET-
12CL, KP004-1ET-12CL through KP007-1ET-12CL, KP008-1ET-12CL through KP012-
1ET-12CL, KP014-1ET-12CL through KP017-1ET-12CL, KP018-1ET-12CL through
25 KP022-1ET-12CL, KP024-1ET-12CL through KP027-1ET-12CL, KP028-1ET-12CL
through KP032-1ET-12CL, KP034-1ET-12CL through KP037-1ET-12CL, KP038-1ET-
12CL through KP042-1ET-12CL, KP044-1ET-12CL through KP047-1ET-12CL, KP048-
1ET-12CL through KP052-1ET-12CL, KP054-1ET-12CL through KP057-1ET-12CL,
KP058-1ET-12CL through KP062-1ET-12CL, KP064-1ET-12CL through KP067-1ET-
30 12CL, KP068-1ET-12CL through KP072-1ET-12CL, KP074-1ET-12CL through KP077-
1ET-12CL, KP078-1ET-12CL through KP082-1ET-12CL, KP084-1ET-12CL through
KP087-1ET-12CL, KP088-1ET-12CL through KP092-1ET-12CL, KP094-1ET-12CL
through KP097-1ET-12CL, KP098-1ET-12CL through KP102-1ET-12CL, KP104-1ET-

12CL through KP107-1ET-12CL, KP108-1ET-12CL through KP112-1ET-12CL, KP114-1ET-12CL through KP117-1ET-12CL, KP118-1ET-12CL through KP122-1ET-12CL, KP124-1ET-12CL through KP127-1ET-12CL, KP128-1ET-12CL through KP132-1ET-12CL, KP134-1ET-12CL through KP137-1ET-12CL, KP138-1ET-12CL through KP142-5 1ET-12CL, KP144-1ET-12CL through KP147-1ET-12CL, KP148-1ET-12CL through KP152-1ET-12CL, KP154-1ET-12CL through KP157-1ET-12CL, KP158-1ET-12CL through KP162-1ET-12CL, KP164-1ET-12CL through KP167-1ET-12CL, KP168-1ET-12CL through KP172-1ET-12CL, KP174-1ET-12CL through KP177-1ET-12CL, KP178-1ET-12CL through KP182-1ET-12CL, KP184-1ET-12CL through KP187-1ET-12CL, 10 KP188-1ET-12CL through KP190-1ET-12CL, KP001-2ET-12CL, KP002-2ET-12CL, KP004-2ET-12CL through KP007-2ET-12CL, KP008-2ET-12CL through KP012-ET-12CL, KP014-2ET-12CL through KP017-2ET-12CL, KP018-2ET-12CL through KP022-2ET-12CL, KP024-2ET-12CL through KP027-2ET-12CL, KP028-2ET-12CL through KP032-2ET-12CL, KP034-2ET-12CL through KP037-2ET-12CL, KP038-2ET-12CL 15 through KP042-2ET-12CL, KP044-2ET-12CL through KP047-2ET-12CL, KP048-2ET-12CL through KP052-2ET-12CL, KP054-2ET-12CL through KP057-2ET-12CL, KP058-2ET-12CL through KP062-2ET-12CL, KP064-2ET-12CL through KP067-2ET-12CL, KP068-2ET-12CL through KP072-2ET-12CL, KP074-2ET-12CL through KP077-2ET-12CL, KP078-2ET-12CL through KP082-2ET-12CL, KP084-2ET-12CL through KP087-20 2ET-12CL, KP088-2ET-12CL through KP092-2ET-12CL, KP094-2ET-12CL through KP097-2ET-12CL, KP098-2ET-12CL through KP102-2ET-12CL, KP104-2ET-12CL through KP107-2ET-12CL, KP108-2ET-12CL through KP112-2ET-12CL, KP114-2ET-12CL through KP117-2ET-12CL, KP118-2ET-12CL through KP122-2ET-12CL, KP124-2ET-12CL through KP127-2ET-12CL, KP128-2ET-12CL through KP132-2ET-12CL, 25 KP134-2ET-12CL through KP137-2ET-12CL, KP138-2ET-12CL through KP142-2ET-12CL, KP144-2ET-12CL through KP147-2ET-12CL, KP148-2ET-12CL through KP152-2ET-12CL, KP154-2ET-12CL through KP157-2ET-12CL, KP158-2ET-12CL through KP162-2ET-12CL, KP164-2ET-12CL through KP167-2ET-12CL, KP168-2ET-12CL through KP172-2ET-12CL, KP174-2ET-12CL through KP177-2ET-12CL, KP178-2ET-30 12CL through KP182-2ET-12CL, KP184-2ET-12CL through KP187-2ET-12CL, KP188-2ET-12CL through KP190-2ET-12CL, KP001-13CL through KP003-13CL, KP005-13CL through KP007-13CL, KP009-13CL through KP013-13CL, KP015-13CL through KP017-13CL, KP019-13CL through KP023-13CL, KP025-13CL through KP027-13CL,

KP029-13CL through KP033-13CL, KP035-13CL through KP037-13CL, KP039-13CL through KP043-13CL, KP045-13CL through KP047-13CL, KP049-13CL through KP053-13CL, KP055-13CL through KP057-13CL, KP059-13CL through KP063-13CL, KP065-13CL through KP067-13CL, KP069-13CL through KP073-13CL, KP075-13CL

5 through KP077-13CL, KP07913CL through KP083-13CL, KP085-13CL through KP087-13CL, KP089-13CL through KP093-13CL, KP095-13CL through KP097-13CL, KP099-13CL through KP103-13CL, KP105-13CL through KP107-13CL, KP109-13CL through KP113-13CL, KP115-13CL through KP117-13CL, KP119-13CL through KP123-13CL, KP125-13CL through KP127-13CL, KP129-13CL through KP133-13CL, KP135-13CL

10 through KP137-13CL, KP139-13CL through KP143-13CL, KP145-13CL through KP147-13CL, KP149-13CL through KP153-13CL, KP155-13CL through KP157-13CL, KP159-13CL through KP163-13CL, KP165-13CL through KP167-13CL, KP169-13CL through KP173-13CL, KP175-13CL through KP177-13CL, KP179-13CL through KP183-13CL, KP185-13CL through KP187-13CL, KP189-13CL, KP190-13CL, KP001-

15 1ET-13CL through KP003-1ET-13CL, KP005-1ET-13CL through KP007-1ET-13CL, KP009-1ET-13CL through KP013-1ET-13CL, KP015-1ET-13CL through KP017-1ET-13CL, KP019-1ET-13CL through KP023-1ET-13CL, KP025-1ET-13CL through KP027-1ET-13CL, KP029-1ET-13CL through KP033-1ET-13CL, KP035-1ET-13CL through KP037-1ET-13CL, KP039-1ET-13CL through KP043-1ET-13CL, KP045-1ET-13CL


20 through KP047-1ET-13CL, KP049-1ET-13CL through KP053-1ET-13CL, KP055-1ET-13CL through KP057-1ET-13CL, KP059-1ET-13CL through KP063-1ET-13CL, KP065-1ET-13CL through KP067-1ET-13CL, KP069-1ET-13CL through KP073-1ET-13CL, KP075-1ET-13CL through KP077-1ET-13CL, KP0791ET-13CL through KP083-1ET-13CL, KP085-1ET-13CL through KP087-1ET-13CL, KP089-1ET-13CL through KP093-

25 1ET-13CL, KP095-1ET-13CL through KP097-1ET-13CL, KP099-1ET-13CL through KP103-1ET-13CL, KP105-1ET-13CL through KP107-1ET-13CL, KP109-1ET-13CL through KP113-1ET-13CL, KP115-1ET-13CL through KP117-1ET-13CL, KP119-1ET-13CL through KP123-1ET-13CL, KP125-1ET-13CL through KP127-1ET-13CL, KP129-1ET-13CL through KP133-1ET-13CL, KP135-1ET-13CL through KP137-1ET-13CL,

30 KP139-1ET-13CL through KP143-1ET-13CL, KP145-1ET-13CL through KP147-1ET-13CL, KP149-1ET-13CL through KP153-1ET-13CL, KP155-1ET-13CL through KP157-1ET-13CL, KP159-1ET-13CL through KP163-1ET-13CL, KP165-1ET-13CL through KP167-1ET-13CL, KP169-1ET-13CL through KP173-1ET-13CL, KP175-1ET-13CL

through KP177-1ET-13CL, KP179-1ET-13CL through KP183-1ET-13CL, KP185-1ET-13CL through KP187-1ET-13CL, KP189-1ET-13CL, KP190-1ET-13CL, KP001-2ET-13CL through KP003-2ET-13CL, KP005-2ET-13CL through KP007-2ET-13CL, KP009-2ET-13CL through KP013-2ET-13CL, KP015-2ET-13CL through KP017-2ET-13CL, 5 KP019-2ET-13CL through KP023-2ET-13CL, KP025-2ET-13CL through KP027-2ET-13CL, KP029-2ET-13CL through KP033-2ET-13CL, KP035-2ET-13CL through KP037-2ET-13CL, KP039-2ET-13CL through KP043-2ET-13CL, KP045-2ET-13CL through KP047-2ET-13CL, KP049-2ET-13CL through KP053-2ET-13CL, KP055-2ET-13CL through KP057-2ET-13CL, KP059-2ET-13CL through KP063-2ET-13CL, KP065-2ET-10 13CL through KP067-2ET-13CL, KP069-2ET-13CL through KP073-2ET-13CL, KP075-2ET-13CL through KP077-2ET-13CL, KP0792ET-13CL through KP083-2ET-13CL, KP085-2ET-13CL through KP087-2ET-13CL, KP089-2ET-13CL through KP093-2ET-13CL, KP095-2ET-13CL through KP097-2ET-13CL, KP099-2ET-13CL through KP103-2ET-13CL, KP105-2ET-13CL through KP107-2ET-13CL, KP109-2ET-13CL through 15 KP113-2ET-13CL, KP115-2ET-13CL through KP117-2ET-13CL, KP119-2ET-13CL through KP123-2ET-13CL, KP125-2ET-13CL through KP127-2ET-13CL, KP129-2ET-13CL through KP133-2ET-13CL, KP135-2ET-13CL through KP137-2ET-13CL, KP139-2ET-13CL through KP143-2ET-13CL, KP145-2ET-13CL through KP147-2ET-13CL, KP149-2ET-13CL through KP153-2ET-13CL, KP155-2ET-13CL through KP157-2ET-20 13CL, KP159-2ET-13CL through KP163-2ET-13CL, KP165-2ET-13CL through KP167-2ET-13CL, KP169-2ET-13CL through KP173-2ET-13CL, KP175-2ET-13CL through KP177-2ET-13CL, KP179-2ET-13CL through KP183-2ET-13CL, KP185-2ET-13CL through KP187-2ET-13CL, KP189-2ET-13CL, and KP190-2ET-13CL; or a pharmaceutically acceptable N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable ester, pharmaceutically acceptable amide, or pharmaceutically acceptable 25 solvate thereof.

96. The compound of claim 1 having the structure



97. A method of modulating a peroxisome proliferator-activated receptor (PPAR) function comprising contacting said PPAR with a compound of Claim 1 and monitoring a change in cell phenotype, cell proliferation, activity of said PPAR, or binding of said PPAR with a natural binding partner.

5 98. The method of Claim 97, wherein said PPAR is selected from the group consisting of PPAR α , PPAR δ , and PPAR γ .

99. A method of inhibiting the formation of adipocytes in a mammal comprising administering a therapeutically effective amount of a compound of Claim 1 to said mammal.

10 100. The method of Claim 99, comprising administering a therapeutically effective amount of a compound of Claim 3 to said mammal.

101. The method of Claim 100, comprising administering a therapeutically effective amount of a compound of Claim 25 to said mammal.

102. The method of Claim 100, comprising administering a therapeutically 15 effective amount of a compound of Claim 26 to said mammal.

103. The method of Claim 100, comprising administering a therapeutically effective amount of a compound of Claim 27 to said mammal.

104. The method of Claim 100, comprising administering a therapeutically effective amount of a compound of Claim 28 to said mammal.

20 105. The method of Claim 100, comprising administering a therapeutically effective amount of a compound of Claim 29 to said mammal.

106. The method of Claim 99, comprising administering a therapeutically effective amount of a compound of Claim 33 to said mammal.

25 107. The method of Claim 106, comprising administering a therapeutically effective amount of a compound of Claim 55 to said mammal.

108. The method of Claim 106, comprising administering a therapeutically effective amount of a compound of Claim 56 to said mammal.


109. The method of Claim 106, comprising administering a therapeutically effective amount of a compound of Claim 57 to said mammal.

30 110. The method of Claim 106, comprising administering a therapeutically effective amount of a compound of Claim 58 to said mammal.


111. The method of Claim 99, comprising administering a therapeutically effective amount of a compound of Claim 63 to said mammal.

112. The method of Claim 111, comprising administering a therapeutically effective amount of a compound of Claim 87 to said mammal.
113. The method of Claim 111, comprising administering a therapeutically effective amount of a compound of Claim 88 to said mammal.
- 5 114. The method of Claim 111, comprising administering a therapeutically effective amount of a compound of Claim 89 to said mammal.
115. The method of Claim 111, comprising administering a therapeutically effective amount of a compound of Claim 90 to said mammal.
- 10 116. A method of treating a disease comprising identifying a patient in need thereof, and administering a therapeutically effective amount of a compound of Claim 1 to said patient.
117. The method of Claim 116, wherein said disease is selected from the group consisting of obesity, diabetes, hyperinsulinemia, polycystic ovary syndrome, climacteric, disorders associated with oxidative stress, inflammatory response to tissue injury, 15 pathogenesis of emphysema, ischemia-associated organ injury, doxorubicin-induced cardiac injury, drug-induced hepatotoxicity, atherosclerosis, and hypertoxic lung injury.
118. The method of Claim 116 wherein the disease is a PPAR modulated disease.
119. The method of Claim 116 wherein the disease is a metabolic disorder or 20 condition.
120. A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable diluent, excipient, or carrier.
121. A pharmaceutical composition comprising a compound of Claim 2 and a pharmaceutically acceptable diluent, excipient, or carrier.
- 25 122. A pharmaceutical composition comprising a compound of Claim 3 and a pharmaceutically acceptable diluent, excipient, or carrier.
123. A pharmaceutical composition comprising a compound of Claim 33 and a pharmaceutically acceptable diluent, excipient, or carrier.
124. A pharmaceutical composition comprising a compound of Claim 63 and a 30 pharmaceutically acceptable diluent, excipient, or carrier.

125. (NEW) A compound having the structure of Formula I:



wherein  is a monocyclic or bicyclic aromatic moiety in which at least one of the ring atoms is N and selected from the group consisting of:



L is selected from the group consisting of a bond and CH_2 ;

k is 1, 2, or 3;

R_1 and R_2 are each independently selected from the group consisting of

a) alkyl, optionally substituted with a substituent selected from the group consisting of hydrogen, lower alkyl, optionally substituted carbocyclic or heterocyclic ring, halogen, perhaloalkyl, hydroxy, alkoxy, nitro, and amino;

b) a six-membered carbocyclic aromatic moiety, or a monocyclic or bicyclic aromatic moiety in which at least one ring atom is N, wherein any such aromatic moiety is optionally substituted with one or more substituents selected from the group consisting of

A) optionally substituted $\text{C}_1\text{-C}_8$ straight-chain, branched, or cyclic saturated or unsaturated alkyl;

B) an alkoxy of formula $-(\text{X}_1)_{n_1}\text{-O-X}_2$, where

X_1 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_2 is selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; and

n_1 is 0 or 1;

- C) halogen or perhaloalkyl;
- D) cyano;
- E) nitro;
- F) an amino of formula $-(X_3)_{n_3}-NX_4X_5$, where

X_3 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_4 and X_5 are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; or X_4 and X_5 , taken together with the nitrogen to which they are attached, form a five-membered or six-membered heteroaromatic or heteroaliphatic ring; and

n_3 is 0 or 1;

- c) perhaloalkyl;
- d) halogen; and
- e) acyl and sulfonyl;

Each R_3 is independently selected from the group consisting of

- a) hydrogen;
- b) alkyl, optionally substituted with a substituent selected from the group consisting of hydrogen, lower alkyl, optionally substituted carbocyclic or heterocyclic ring, halogen, perhaloalkyl, hydroxy, alkoxy, nitro, and amino;
- c) a five-membered or six-membered heteroaryl ring or a six-membered aryl ring, optionally substituted with one or more substituents selected from the group consisting of

A) optionally substituted C₁-C₈ straight-chain, branched, or cyclic saturated or unsaturated alkyl;

B) an alkoxy of formula $-(X_1)_{n_1}-O-X_2$, where

X_1 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_2 is selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; and

$n1$ is 0 or 1;

- C) halogen or perhaloalkyl;
- D) cyano;
- E) nitro;
- F) an amino of formula $-(X_3)_{n3}-NX_4X_5$, where

X_3 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_4 and X_5 are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; or X_4 and X_5 , taken together with the nitrogen to which they are attached, form a five-membered or six-membered heteroaromatic or heteroaliphatic ring; and

$n3$ is 0 or 1;


- d) perhaloalkyl;
- e) halogen; and
- f) acyl and sulfonyl; and

R_4 is selected from the group consisting of


- a) hydrogen;
- b) alkyl, optionally substituted with a substituent selected from the group consisting of hydrogen, lower alkyl, optionally substituted carbocyclic or heterocyclic ring; and
- c) a five-membered or six-membered heteroaryl ring or a six-membered aryl ring, optionally substituted with one or more substituents selected from the group consisting of optionally substituted C₁-C₈ straight-chain, branched, or cyclic saturated or unsaturated alkyl;

or a pharmaceutically acceptable N-oxide, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester, pharmaceutically acceptable amide, or pharmaceutically acceptable solvate thereof.


126. (NEW) The compound of Claim 1 selected from the group consisting of:



,



, and



;

wherein Ar_2 is a monocyclic or bicyclic aromatic moiety in which at least one of the ring atoms is N;

one of $Q_1 - Q_5$ is nitrogen and the rest are carbon, wherein said carbon is optionally substituted with hydrogen, R_3 , or $-\text{C}(\text{O})\text{OR}_4$; and

R_5 is selected from the group consisting of

- hydrogen;
- alkyl, optionally substituted with a substituent selected from the group consisting of hydrogen, lower alkyl, optionally substituted carbocyclic or heterocyclic ring, halogen, perhaloalkyl, hydroxy, alkoxy, nitro, and amino;
- a five-membered or six-membered heteroaryl ring or a six-membered aryl ring, optionally substituted with one or more substituents selected from the group consisting of
 - optionally substituted $\text{C}_1\text{-C}_8$ straight-chain, branched, or cyclic saturated or unsaturated alkyl;
 - an alkoxy of formula $-(X_1)_{n1}\text{-O-}X_2$, where X_1 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl; X_2 is selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; and $n1$ is 0 or 1;

- C) halogen or perhaloalkyl;
- D) cyano;
- E) nitro;
- F) an amino of formula $-(X_3)_{n3}-NX_4X_5$, where


X_3 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_4 and X_5 are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; or X_4 and X_5 , taken together with the nitrogen to which they are attached, form a five-membered or six-membered heteroaromatic or heteroaliphatic ring; and


$n3$ is 0 or 1;

- d) perhaloalkyl;
- e) halogen; and
- f) acyl and sulfonyl.

127. (NEW) The compound of Claim 2 having the structure:



wherein Ar_2 is selected from the group consisting of:



128. (NEW) The compound of Claim 3, wherein R_1 is alkyl, optionally substituted with one or more optionally substituted carbocyclic or heterocyclic rings.

129. (NEW) The compound of Claim 4, wherein said alkyl is a lower alkyl.

130. (NEW) The compound of Claim 5, wherein said lower alkyl is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, and sec-butyl.

131. (NEW) The compound of Claim 4, wherein said carbocyclic ring is phenyl.

132. (NEW) The compound of Claim 7, wherein said phenyl is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, halogen, perhaloalkyl, hydroxyl, alkoxy, nitro, and amino.

133. (NEW) The compound of Claim 8, wherein said substituent is perhaloalkyl.

134. (NEW) The compound of Claim 9, wherein said perhaloalkyl is trifluoromethyl.

135. (NEW) The compound of Claim 4, wherein the carbocyclic ring is 2,4-bis(trifluoromethyl)phenyl.

136. (NEW) The compound of Claim 3, wherein R5 is optionally substituted alkyl.

137. (NEW) The compound of Claim 12, wherein said alkyl is a lower alkyl.

138. (NEW) The compound of Claim 13, wherein said lower alkyl is selected from the group consisting of methyl, ethyl, n-propyl, n-butyl, and sec-butyl.

139. (NEW) The compound of Claim 14, wherein R5 is ethyl

140. (NEW) The compound of Claim 3, where R5 is hydrogen or optionally substituted alkyl

141. (NEW) The compound of Claim 16, wherein said alkyl is a lower alkyl

142. (NEW) The compound of Claim 17, wherein said lower alkyl is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, and sec-butyl

143. (NEW) The compound of Claim 3, wherein R3 is methyl

144. (NEW) The compound of Claim 3, wherein R3 is hydrogen

Applicants respectfully submit that the claims are ready for examination and in condition for allowance.

Respectfully submitted,

/Dennis A. Bennett/

Dennis A. Bennett
Reg. 34,547
Date: July 16, 2007

Global Patent Group
10411 Clayton Road
Suite 304
St. Louis, MO 63131
Telephone: 314-567-7788